| Type | Title | Date Released | |
|---|---|---|---|
EFFECT | Form EFFECT | ||
424B3 | SHARE RESALE REGISTRATION | Offering amount: $29,800,324 | Shares: 1,013,041 | ||
DEF 14A | Form DEF 14A | ||
S-1 | C/M Capital Master Fund, LP - SPA - Fixed Purchase: 95% of the lower of prior-five-day VWAP and day's low, capped at day's close; VWAP Purchase: 95% of the lower of day's close and unspecified-period VWAP; both subject to lower-issuance resets. Up to $20 million daily ($10 million each type). $3.40 VWAP Purchase/$3.60 Fixed Purchase floors; 9.99% ownership cap. EFFECTIVE, DATED 2026-11-03 | ||
8-K | Endovia Health Sciences Amends ELOC Agreement to Increase Commitment to $135 Million | ||
PRE 14A | Form PRE 14A | ||
SCHEDULE 13G | C/M CAPITAL PARTNERS, LP (Filed by) | ||
8-K | Endovia Health Sciences Amends Purchase Agreement with C/M Capital Master Fund to Increase Beneficial Ownership Limitation | ||
DEFA14A | Form DEFA14A | ||
8-K | Endovia Health Sciences Reports Unregistered Sale of Common Stock | ||
DEF 14A | Form DEF 14A | ||
8-K | Endovia and Lupvindol Announce FDA Minor Use Determination for CannEpil® in Canine Bone Cancer Pain |
